Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$93.32 +3.4%	$110.02	$76.53 ▼ $131.49	$22.39B	0.3	836,484 shs	1.25 million shs
INO Inovio Pharmaceuticals	$1.66 +10.7%	$1.99	$1.48 ▼ $13.44	$60.87M	0.92	562,534 shs	844,292 shs
JNJ Johnson & Johnson	$155.41 +1.4%	$159.16	$140.68 ▼ $169.99	$374.51B	0.47	7.74 million shs	10.35 million shs
MRNA Moderna	$27.72 +2.1%	$34.43	$26.32 ▼ $170.47	$10.72B	1.86	6.94 million shs	11.79 million shs
PFE Pfizer	$24.73 +0.8%	$26.00	$24.33 ▼ $31.54	$140.26B	0.61	39.24 million shs	41.78 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	-0.85%	-6.97%	-20.04%	-20.76%	-3.04%
INO Inovio Pharmaceuticals	-7.98%	-17.13%	-24.24%	-18.03%	-88.57%
JNJ Johnson & Johnson	-7.62%	-4.90%	-7.25%	+5.96%	-2.87%
MRNA Moderna	-4.20%	-19.76%	-12.27%	-34.68%	-74.28%
PFE Pfizer	-3.27%	-4.05%	-7.21%	-7.56%	-11.46%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BNTX BioNTech	2.8266 of 5 stars	4.4	2.0	0.0	0.0	2.4	0.8	0.6
INO Inovio Pharmaceuticals	3.9662 of 5 stars	3.3	2.0	0.0	4.3	3.3	0.0	1.3
JNJ Johnson & Johnson	4.7527 of 5 stars	3.3	3.0	4.2	3.9	2.6	2.5	1.3
MRNA Moderna	4.3993 of 5 stars	4.0	1.0	0.0	4.6	2.4	2.5	1.3
PFE Pfizer	4.9845 of 5 stars	3.3	3.0	4.2	4.2	3.3	3.3	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTX BioNTech	2.89	Moderate Buy	$143.44	53.71% Upside
INO Inovio Pharmaceuticals	2.60	Moderate Buy	$12.20	634.94% Upside
JNJ Johnson & Johnson	2.56	Moderate Buy	$171.33	10.25% Upside
MRNA Moderna	2.04	Hold	$59.00	112.84% Upside
PFE Pfizer	2.63	Moderate Buy	$31.92	29.09% Upside

Current Analyst Ratings Breakdown

Latest JNJ, MRNA, PFE, INO, and BNTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/2/2025	JNJ Johnson & Johnson	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$181.00 ➝ $181.00
4/2/2025	JNJ Johnson & Johnson	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
4/1/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$150.00 ➝ $145.00
3/21/2025	MRNA Moderna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$40.00 ➝ $33.00
3/19/2025	INO Inovio Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$6.00 ➝ $5.00
3/19/2025	INO Inovio Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$3.00 ➝ $3.00
3/18/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/13/2025	BNTX BioNTech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$145.00
3/13/2025	MRNA Moderna	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$40.00
3/12/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/11/2025	BNTX BioNTech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$145.00 ➝ $139.00

(Data available from 4/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTX BioNTech	$2.75B	8.14	$4.01 per share	23.25	$92.17 per share	1.01
INO Inovio Pharmaceuticals	$217.76K	279.52	N/A	N/A	$5.16 per share	0.32
JNJ Johnson & Johnson	$88.82B	4.22	$12.77 per share	12.17	$29.69 per share	5.23
MRNA Moderna	$3.20B	3.35	N/A	N/A	$28.33 per share	0.98
PFE Pfizer	$63.63B	2.20	$3.88 per share	6.38	$15.81 per share	1.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTX BioNTech	$1.01B	-$3.00	N/A	N/A	N/A	-15.16%	-2.35%	-2.05%	5/5/2025 (Estimated)
INO Inovio Pharmaceuticals	-$135.12M	-$3.99	N/A	N/A	N/A	N/A	-118.17%	-83.47%	5/12/2025 (Estimated)
JNJ Johnson & Johnson	$14.07B	$6.65	23.37	14.04	2.56	18.20%	34.24%	13.63%	4/15/2025 (Estimated)
MRNA Moderna	-$3.56B	-$9.28	N/A	N/A	N/A	-110.04%	-28.74%	-21.83%	5/1/2025 (Estimated)
PFE Pfizer	$8.03B	$1.41	17.54	8.16	0.64	12.62%	19.47%	8.09%	4/29/2025 (Estimated)

Latest JNJ, MRNA, PFE, INO, and BNTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/29/2025	N/A	PFE Pfizer	$0.67	N/A	N/A	N/A	$14.43 billion	N/A
4/15/2025	N/A	JNJ Johnson & Johnson	$2.59	N/A	N/A	N/A	$21.65 billion	N/A
3/18/2025	Q4 2024	INO Inovio Pharmaceuticals	-$0.87	-$0.69	+$0.18	-$0.60	$0.03 million	$0.12 million
3/10/2025	Q4 24	BNTX BioNTech	$0.38	$1.08	+$0.70	$1.15	$1.24 billion	$1.19 billion
2/4/2025	Q4 2024	PFE Pfizer	$0.48	$0.63	+$0.15	$0.07	$17.26 billion	$17.76 billion
1/22/2025	Q4 2024	JNJ Johnson & Johnson	$1.99	$2.04	+$0.05	$1.41	$22.44 billion	$22.52 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTX BioNTech	$1.53	1.64%	N/A	N/A	N/A
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
JNJ Johnson & Johnson	$4.96	3.19%	+5.43%	74.59%	63 Years
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	6.96%	+2.50%	121.99%	16 Years

Latest JNJ, MRNA, PFE, INO, and BNTX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
1/2/2025	JNJ Johnson & Johnson	quarterly	$1.24	3.43%	2/18/2025	2/18/2025	3/4/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTX BioNTech	0.01	7.33	7.21
INO Inovio Pharmaceuticals	N/A	3.88	3.88
JNJ Johnson & Johnson	0.43	1.11	0.86
MRNA Moderna	N/A	3.67	3.62
PFE Pfizer	0.63	1.00	0.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTX BioNTech	15.52%
INO Inovio Pharmaceuticals	26.79%
JNJ Johnson & Johnson	69.55%
MRNA Moderna	75.33%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
BNTX BioNTech	19.20%
INO Inovio Pharmaceuticals	2.50%
JNJ Johnson & Johnson	0.16%
MRNA Moderna	11.00%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTX BioNTech	3,080	239.97 million	193.71 million	Optionable
INO Inovio Pharmaceuticals	320	36.67 million	25.45 million	Optionable
JNJ Johnson & Johnson	152,700	2.41 billion	2.40 billion	Optionable
MRNA Moderna	3,900	386.62 million	324.40 million	Optionable
PFE Pfizer	83,000	5.67 billion	5.66 billion	Optionable

JNJ, MRNA, PFE, INO, and BNTX Headlines

Recent News About These Companies

Pfizer (PFE) Increases Yet Falls Behind Market: What Investors Need to Know

April 2 at 6:50 PM | zacks.com

UK's Health Agency Endorses Pfizer's Blood Cancer Combo Therapy As First For Untreated Hodgkin Lymphoma Patients

April 2 at 4:32 PM | benzinga.com

Pfizer (NYSE:PFE) Shares Up 0.6% - Time to Buy?

April 2 at 1:19 PM | marketbeat.com

Pfizer (NYSE:PFE) Expands RSV Vaccine Use In Europe Amid 3% Share Price Dip

April 2 at 12:40 PM | finance.yahoo.com

PFE, MRK, LLY & Other Drug Stocks Down Amid Tariff Jitters

April 2 at 10:46 AM | zacks.com

Pfizer (NYSE:PFE) Sets New 1-Year Low - What's Next?

April 2 at 10:29 AM | marketbeat.com

Proxy adviser ISS recommends Pfizer shareholders to vote against CEO compensation

April 2 at 9:10 AM | reuters.com

PFE Secures EU Nod for Expanded Use of RSV Vaccine Abrysvo

April 2 at 8:40 AM | zacks.com

Wall Street Says Sell US Market Rallies: Never Sell These 4 High-Yield Dividend Giants

April 2 at 7:47 AM | 247wallst.com

SevenBridge Financial Group LLC Sells 37,323 Shares of Pfizer Inc. (NYSE:PFE)

April 2 at 7:29 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Position Boosted by Private Portfolio Partners LLC

April 2 at 6:43 AM | marketbeat.com

Te Ahumairangi Investment Management Ltd Reduces Position in Pfizer Inc. (NYSE:PFE)

April 2 at 6:35 AM | marketbeat.com

Columbia Asset Management Sells 28,637 Shares of Pfizer Inc. (NYSE:PFE)

April 2 at 6:34 AM | marketbeat.com

Massachusetts Financial Services Co. MA Boosts Holdings in Pfizer Inc. (NYSE:PFE)

April 2 at 6:34 AM | marketbeat.com

RFG Bristol Wealth Advisors LLC Invests $552,000 in Pfizer Inc. (NYSE:PFE)

April 2 at 6:33 AM | marketbeat.com

Groupama Asset Managment Reduces Stake in Pfizer Inc. (NYSE:PFE)

April 2 at 6:17 AM | marketbeat.com

StoneX Group Inc. Boosts Holdings in Pfizer Inc. (NYSE:PFE)

April 2 at 5:46 AM | marketbeat.com

Alliancebernstein L.P. Cuts Stake in Pfizer Inc. (NYSE:PFE)

April 2 at 5:18 AM | marketbeat.com

O Shaughnessy Asset Management LLC Sells 254,639 Shares of Pfizer Inc. (NYSE:PFE)

April 2 at 4:56 AM | marketbeat.com

2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating

April 1 at 7:49 PM | marketbeat.com

2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating

April 1 at 7:49 PM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Warren Buffett Swaps VOO for This Reliable Dividend Stock
By Sarah Horvath | March 7, 2025
View Warren Buffett Swaps VOO for This Reliable Dividend Stock
NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
By Thomas Hughes | March 12, 2025
View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares
By Jea Yu | March 11, 2025
View Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares
Resilient Investing: 3 Stocks Built to Weather Market Volatility
By Jeffrey Neal Johnson | March 17, 2025
View Resilient Investing: 3 Stocks Built to Weather Market Volatility
2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating
By Gabriel Osorio-Mazilli | April 1, 2025
View 2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating

JNJ, MRNA, PFE, INO, and BNTX Company Descriptions

BioNTech NASDAQ:BNTX

$93.32 +3.03 (+3.36%)

Closing price 04:00 PM Eastern

Extended Trading

$91.94 -1.38 (-1.48%)

As of 07:53 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Inovio Pharmaceuticals NASDAQ:INO

$1.66 +0.16 (+10.67%)

Closing price 04:00 PM Eastern

Extended Trading

$1.63 -0.03 (-1.81%)

As of 07:59 PM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Johnson & Johnson NYSE:JNJ

$155.41 +2.16 (+1.41%)

Closing price 03:58 PM Eastern

Extended Trading

$154.95 -0.46 (-0.30%)

As of 07:59 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Moderna NASDAQ:MRNA

$27.72 +0.56 (+2.06%)

Closing price 04:00 PM Eastern

Extended Trading

$26.50 -1.22 (-4.38%)

As of 07:59 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Pfizer NYSE:PFE

$24.73 +0.19 (+0.77%)

Closing price 03:59 PM Eastern

Extended Trading

$24.47 -0.26 (-1.05%)

As of 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest JNJ, MRNA, PFE, INO, and BNTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest JNJ, MRNA, PFE, INO, and BNTX Earnings

Compare Dividends

Latest JNJ, MRNA, PFE, INO, and BNTX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

JNJ, MRNA, PFE, INO, and BNTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

JNJ, MRNA, PFE, INO, and BNTX Company Descriptions

BioNTech NASDAQ:BNTX

Inovio Pharmaceuticals NASDAQ:INO

Johnson & Johnson NYSE:JNJ

Moderna NASDAQ:MRNA

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools